The Indian pharmaceutical market (IPM) clocked Rs 6597 crores in April 2014 and has seen a growth of 5.2 per cent. Amongst the top 10 companies, Mankind grew at 11.3 per cent followed by Lupin at 9.5 per cent and Sun Pharma at 8.6 per cent. 31 corporates have crossed the growth of IPM amongst top 50.
Amongst the top 50 corporates, Akumentis has the highest growth of 46.6 per cent followed by Ajanta at 39 per cent and Biocon at 35.3 per cent. Amongst the 11-20 ranked companies, Macleods has shown high growth at 25.6 per cent followed by Aristo at 18.7 per cent and Torrent at 14.5 per cent. Amongst the 50-75 ranked corporates, Corona shows high growth at 34.9 per cent followed by Apex at 33 per cent and Pharmed at 28.2 per cent.
Amongst the 76-100 ranked corporates, Gland Pharma has grown the fastest at 46.6 per cent. Indian companies have grown at 7.9 per cent versus -1.6 per cent for MNCs in April 2014. Amongst the top 50 in MNCs MSD grew the highest at 13.5 per cent, followed by Merck at 9.1 per cent and AstraZeneca at 5.5 per cent. Under the Non-NLEM category, Indian companies are growing at 10.4 per cent whereas MNCs at 1.6 per cent.
Withbonus units at full value (Val in Crs) | ||||||||
Val in Crs | Rank | MAT Apr -14 | Apr-14 | |||||
CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 76055 | 100.00 | 5.9 | 6597 | 100.00 | 5.2 | ||
| Abbott + Abbott HC + Novo | 1 | 1 | 4880 | 6.42 | 4.2 | 414 | 6.28 | 0.0 |
| Sun Pharma | 2 | 2 | 4117 | 5.41 | 15.9 | 360 | 5.46 | 8.6 |
| Cipla | 3 | 3 | 3789 | 4.98 | 6.5 | 342 | 5.18 | 7.9 |
| Zydus + Biochem | 4 | 4 | 3359 | 4.42 | 7.8 | 291 | 4.41 | 6.0 |
| Ranbaxy | 5 | 6 | 2861 | 3.76 | -1.8 | 229 | 3.47 | -6.7 |
| Glaxo | 6 | 8 | 2730 | 3.59 | -15.4 | 225 | 3.40 | -11.2 |
| Mankind | 7 | 5 | 2699 | 3.55 | 5.0 | 245 | 3.71 | 11.3 |
| Alkem + Cachet + Indchemie | 8 | 9 | 2660 | 3.50 | 10.5 | 224 | 3.39 | 6.2 |
| Lupin | 9 | 7 | 2555 | 3.36 | 11.7 | 226 | 3.42 | 9.5 |
| Pfizer | 10 | 10 | 2218 | 2.92 | 3.0 | 197 | 2.98 | 4.2 |
| Emcure + Zuventus | 11 | 12 | 2142 | 2.82 | 14.7 | 183 | 2.77 | 11.6 |
| Macleods | 12 | 11 | 2018 | 2.65 | 10.3 | 190 | 2.89 | 25.6 |
| Sanofi | 13 | 15 | 1922 | 2.53 | -0.1 | 159 | 2.41 | -6.1 |
| Intas | 14 | 13 | 1896 | 2.49 | 7.7 | 167 | 2.54 | 3.6 |
| Aristo | 15 | 14 | 1851 | 2.43 | 13.4 | 162 | 2.46 | 18.7 |
| Glenmark | 16 | 16 | 1651 | 2.17 | 15.7 | 141 | 2.14 | 10.3 |
The DPCO 2013 containing molecules market was at –11.5 per cent whereas the non-DPCO market grew by eight per cent resulting in an overall growth of 5.2 per cent for April 2014. The DPCO 2013 portfolio for Pfizer de-grew at 26.9 per cent, GSK de-grew at 19.5 per cent and Ranbaxy de-grew by 25 per cent.
From therapy perspective, nine therapies have outgrown the IPM growth and five therapies have double digit growths. The respiratory market grew at 13.6 per cent, gastrointestinal market grew at 4.3 per cent whereas anti-infectives grew at 0.4 per cent. The anti-diabetic market grows at 14.1 per cent and cardiac at 4.8 per cent in chronic business. The derma market grew by 11.1 per cent.
From a regional perspective 13 regions have outgrown the IPM growth. The Vidarbha market grew the highest at 15.1 per cent followed by MP Market at 12.5 per cent. Three regions had negative growths in April 2014.
Val in Crs | MAT Apr 14 | MNTH APR 14 | ||
Super Group | VAL IN CRS | GR% | VAL IN CRS | GR% |
IPM | 76055 | 5.9 | 6597 | 5.2 |
| ANTI-INFECTIVES | 12579 | 0.3 | 1006 | 0.4 |
| CARDIAC | 9451 | 7.9 | 842 | 4.8 |
| GASTRO INTESTINAL | 8530 | 5.4 | 774 | 4.3 |
| VITAMINS / MINERALS / NUTRIENTS | 6803 | 5.1 | 602 | 4.0 |
| RESPIRATORY | 5972 | 9.7 | 492 | 13.6 |
| PAIN / ANALGESICS | 5466 | 3.8 | 473 | 3.2 |
| ANTI DIABETIC | 5429 | 15.3 | 504 | 14.1 |
| NEURO / CNS | 4751 | 6.4 | 413 | 0.8 |
| GYNAECOLOGICAL | 4716 | 1.4 | 421 | 3.9 |
| DERMA | 4339 | 11.6 | 379 | 11.1 |
| OPHTHAL / OTOLOGICALS | 1359 | 8.0 | 128 | 7.9 |
| HORMONES | 1295 | 4.3 | 115 | 6.9 |
| VACCINES | 1104 | -2.6 | 84 | -13.1 |
| ANTI-NEOPLASTICS | 1054 | 29.1 | 96 | 26.9 |
| BLOOD RELATED | 927 | 3.8 | 79 | 3.9 |
| OTHERS | 886 | 3.9 | 81 | 5.9 |
| ANTI MALARIALS | 624 | 1.6 | 41 | 11.4 |
| SEX STIMULANTS / REJUVENATORS | 430 | 4.6 | 37 | 0.2 |
| STOMATOLOGICALS | 341 | 8.1 | 31 | 8.3 |
Amongst the top brands in the IPM, Glycomet GP (34.5 per cent), Galvus Met (28.8 per cent), Skinlite (22.9 per cent), Telma (22.4), Liv-52 (15.9 per cent) amongst top 25 Brands grew amongst the fastest over April-13.
A total of 123 brands launched in April 2014. Getlite, Straieout, Picnovit are the top NIs for the month of April 2014.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -
